FDA grants $INMB an aligned Phase 2b/3 pathway for its early Alzheimers drug, XPro1595. Meanwhile, $NVCR's Optune Pax gains FDA approval for pancreatic cancer, marking a significant advancement.
This topic pertains to biotechnology and pharmaceutical companies, focusing on drug development, regulatory approvals, and clinical trial updates.
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing